ArticleTherapeutic advances in medical oncology2025

HRR deficiency-guided use of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer: a cost-effectiveness analysis.

Mingjun Rui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.